Borealisbio
Founded 2024 · 57 employees on LinkedIn · 2 known investors
Find your way into Borealisbio
Borealis develops RNA medicines to treat kidney diseases. The company was founded by the team behind Chinook Therapeutics, which Novartis acquired in 2023, and focuses on kidney disease indications with unmet medical need.
Investors · 2
Competitors · 4
by search overlap
IQVIA14 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Chrysalis Biotherapeutics12 shared keywordsChrysalis Biotherapeutics is a clinical-stage biopharmaceutical company developing peptide therapeutics, led by its drug candidate TP508 (Rusalatide acetate, Chrysalin), which activates endothelial and stem cells to repair tissue after severe viral infection or nuclear radiation. Its immediate target is treating mild to moderate acute respiratory distress syndrome (ARDS) to reduce mortality.
Fortis Life Sciences9 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Companies competing with Borealisbio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Borealisbio do?
- Borealis develops RNA medicines to treat kidney diseases. The company was founded by the team behind Chinook Therapeutics, which Novartis acquired in 2023, and focuses on kidney disease indications with unmet medical need.
- Who are Borealisbio's investors?
- Borealisbio's investors include Westlake Village BioPartners, Versant Ventures.